Literature DB >> 17823927

WWOX hypomorphic mice display a higher incidence of B-cell lymphomas and develop testicular atrophy.

John H Ludes-Meyers1, Hyunsuk Kil, Maria I Nuñez, Claudio J Conti, Jan Parker-Thornburg, Mark T Bedford, C Marcelo Aldaz.   

Abstract

WWOX is a putative tumor suppressor gene encoded within common chromosomal fragile site region FRA16D, in chromosome band 16q23. Multiple studies have demonstrated that WWOX expression is often reduced or lost in various tumor types. WWOX tumor suppressor activity was suggested by re-expressing WWOX in breast, ovarian, and lung tumor cell lines leading to tumor growth inhibition in vivo. To determine whether loss of Wwox gene expression has a role in tumorigenesis, we generated a mouse strain containing a Wwox gene mutated by a gene-trap vector. Homozygous Wwox gene-trap mice (Wwox(gt/gt)) had no detectable Wwox protein in most tissues examined, although, a low level could be detected in a minority of tissues. Because of these observations, we concluded that these mice are Wwox hypomorphs. Remarkably, Wwox hypomorphic mice are viable in contrast to the recently reported postnatal lethality of Wwox knockout mice. Testes from Wwox(gt/gt) males had high numbers of atrophic seminiferous tubules and reduced fertility when compared with wild-type counterparts. We observed that the Wwox(gt/gt) mice had a significantly shorter lifespan, and female hypomorphs had a higher incidence of spontaneous B-cell lymphomas. In conclusion, we describe a novel Wwox hypomorphic mouse model that overcomes postnatal lethality that was recently observed in Wwox knockout mice. Therefore, tumorigenesis studies using this model more closely recapitulates the loss of WWOX expression observed in human cancers. Importantly, our observation that Wwox hypomorphs had an increased incidence of B-cell lymphomas supports a role of Wwox as a tumor suppressor. (c) 2007 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17823927      PMCID: PMC4143238          DOI: 10.1002/gcc.20497

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  25 in total

1.  Unique patterns of gene expression changes in liver after treatment of mice for 2 weeks with different known carcinogens and non-carcinogens.

Authors:  Mari Iida; Colleen H Anna; Wanda M Holliday; Jennifer B Collins; Michael L Cunningham; Robert C Sills; Theodora R Devereux
Journal:  Carcinogenesis       Date:  2004-12-23       Impact factor: 4.944

2.  Genealogy of the 129 inbred strains: 129/SvJ is a contaminated inbred strain.

Authors:  D W Threadgill; D Yee; A Matin; J H Nadeau; T Magnuson
Journal:  Mamm Genome       Date:  1997-06       Impact factor: 2.957

3.  Fragile genes as biomarkers: epigenetic control of WWOX and FHIT in lung, breast and bladder cancer.

Authors:  Dimitrios Iliopoulos; Gulnur Guler; Shuang-Yin Han; Danika Johnston; Teresa Druck; Kelly A McCorkell; Juan Palazzo; Peter A McCue; Raffaele Baffa; Kay Huebner
Journal:  Oncogene       Date:  2005-02-24       Impact factor: 9.867

4.  The common fragile site FRA16D and its associated gene WWOX are highly conserved in the mouse at Fra8E1.

Authors:  Kurt A Krummel; Stacy R Denison; Eric Calhoun; Leslie A Phillips; David I Smith
Journal:  Genes Chromosomes Cancer       Date:  2002-06       Impact factor: 5.006

5.  Frequent loss of WWOX expression in breast cancer: correlation with estrogen receptor status.

Authors:  María I Nunez; John Ludes-Meyers; Martín C Abba; Hyunsuk Kil; Nancy W Abbey; Robert E Page; Aysegul Sahin; Andrés J P Klein-Szanto; C Marcelo Aldaz
Journal:  Breast Cancer Res Treat       Date:  2005-01       Impact factor: 4.872

6.  Efficiency assessment of the gene trap approach.

Authors:  A K Voss; T Thomas; P Gruss
Journal:  Dev Dyn       Date:  1998-06       Impact factor: 3.780

7.  Expression of FRA16D/WWOX and FRA3B/FHIT genes in hematopoietic malignancies.

Authors:  Hideshi Ishii; Andrea Vecchione; Yutaka Furukawa; Krittaya Sutheesophon; Shuang-Yin Han; Teresa Druck; Tamotsu Kuroki; Francesco Trapasso; Miki Nishimura; Yasushi Saito; Keiya Ozawa; Carlo M Croce; Kay Huebner; Yusuke Furukawa
Journal:  Mol Cancer Res       Date:  2003-11       Impact factor: 5.852

8.  Expression profiling in primates reveals a rapid evolution of human transcription factors.

Authors:  Yoav Gilad; Alicia Oshlack; Gordon K Smyth; Terence P Speed; Kevin P White
Journal:  Nature       Date:  2006-03-09       Impact factor: 49.962

9.  WWOX, the common chromosomal fragile site, FRA16D, cancer gene.

Authors:  J H Ludes-Meyers; A K Bednarek; N C Popescu; M Bedford; C M Aldaz
Journal:  Cytogenet Genome Res       Date:  2003       Impact factor: 1.636

10.  Frequent downregulation and loss of WWOX gene expression in human hepatocellular carcinoma.

Authors:  S-W Park; J Ludes-Meyers; D B Zimonjic; M E Durkin; N C Popescu; C M Aldaz
Journal:  Br J Cancer       Date:  2004-08-16       Impact factor: 7.640

View more
  39 in total

1.  A multi-exon deletion within WWOX is associated with a 46,XY disorder of sex development.

Authors:  Stefan White; Jacqueline Hewitt; Erin Turbitt; Yvonne van der Zwan; Remko Hersmus; Stenvert Drop; Peter Koopman; Vincent Harley; Martine Cools; Leendert Looijenga; Andrew Sinclair
Journal:  Eur J Hum Genet       Date:  2011-11-09       Impact factor: 4.246

Review 2.  Phosphorylation/de-phosphorylation in specific sites of tumor suppressor WWOX and control of distinct biological events.

Authors:  Shenq-Shyang Huang; Nan-Shan Chang
Journal:  Exp Biol Med (Maywood)       Date:  2018-01-08

Review 3.  DSDs: genetics, underlying pathologies and psychosexual differentiation.

Authors:  Valerie A Arboleda; David E Sandberg; Eric Vilain
Journal:  Nat Rev Endocrinol       Date:  2014-08-05       Impact factor: 43.330

4.  Recurrent alterations of the WW domain containing oxidoreductase gene spanning the common fragile site FRA16D in multiple myeloma and monoclonal gammopathy of undetermined significance.

Authors:  Hiroshi Handa; Yoshiko Sasaki; Hikaru Hattori; Lobna Alkebsi; Tetsuhiro Kasamatsu; Takayuki Saitoh; Takeki Mitsui; Akihiko Yokohama; Norifumi Tsukamoto; Morio Matsumoto; Hirokazu Murakami
Journal:  Oncol Lett       Date:  2017-07-26       Impact factor: 2.967

Review 5.  Strategies of oncogenic microbes to deal with WW domain-containing oxidoreductase.

Authors:  Yao Chang; Yu-Yan Lan; Jenn-Ren Hsiao; Nan-Shan Chang
Journal:  Exp Biol Med (Maywood)       Date:  2014-12-07

6.  Conditional inactivation of the mouse Wwox tumor suppressor gene recapitulates the null phenotype.

Authors:  Suhaib K Abdeen; Sara Del Mare; Sadeeq Hussain; Muhannad Abu-Remaileh; Zaidoun Salah; John Hagan; Maysoon Rawahneh; Xin-An Pu; Stacey Russell; Janet L Stein; Gary S Stein; Jane B Lian; Rami I Aqeilan
Journal:  J Cell Physiol       Date:  2013-07       Impact factor: 6.384

Review 7.  WWOX at the crossroads of cancer, metabolic syndrome related traits and CNS pathologies.

Authors:  C Marcelo Aldaz; Brent W Ferguson; Martin C Abba
Journal:  Biochim Biophys Acta       Date:  2014-06-14

8.  Genome wide DNA-profiling of HIV-related B-cell lymphomas.

Authors:  Daniela Capello; Marta Scandurra; Giulia Poretti; Paola M V Rancoita; Michael Mian; Annunziata Gloghini; Clara Deambrogi; Maurizio Martini; Davide Rossi; Timothy C Greiner; Wing C Chan; Maurilio Ponzoni; Santiago M Moreno; Miguel A Piris; Vincenzo Canzonieri; Michele Spina; Umberto Tirelli; Giorgio Inghirami; Andrea Rinaldi; Emanuele Zucca; Riccardo D Favera; Franco Cavalli; Luigi Maria Larocca; Ivo Kwee; Antonino Carbone; Gianluca Gaidano; Francesco Bertoni
Journal:  Br J Haematol       Date:  2009-10-12       Impact factor: 6.998

Review 9.  Translational genetics for diagnosis of human disorders of sex development.

Authors:  Ruth M Baxter; Eric Vilain
Journal:  Annu Rev Genomics Hum Genet       Date:  2013-07-15       Impact factor: 8.929

10.  Generation and characterization of mice carrying a conditional allele of the Wwox tumor suppressor gene.

Authors:  John H Ludes-Meyers; Hyunsuk Kil; Jan Parker-Thornburg; Donna F Kusewitt; Mark T Bedford; C Marcelo Aldaz
Journal:  PLoS One       Date:  2009-11-10       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.